Eugia is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $5.8B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Eugia's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | FDA-approved 30 Oct 2020; first filer; FDA has not decided whether it keeps 180-day shared exclusivity | $2.7B |
| Jakafi | Incyte | Generic | 2028 | Filed with the FDA; settled, terms confidential | $3.1B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Eugia's share of it.
Eugia has FDA approval for Pomalyst, with no US launch confirmed; and applications filed for Jakafi. It has settled with the brand owner over 1 drug. Of the 70 makers we follow, 31 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.